David H Vesole
Overview
Explore the profile of David H Vesole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
4317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Fritz A, Akhtar O, Freeman C, Cowan A, Shah N, et al.
Leukemia
. 2025 Feb;
PMID: 39994463
No abstract available.
2.
Waszczuk-Gajda A, Vesole D, Malyszko J, Jurczyszyn A, Wrobel T, Drozd-Sokolowska J, et al.
Arch Med Sci
. 2025 Feb;
20(6):1864-1873.
PMID: 39967949
Introduction: The prognostic factors in autotransplanted multiple myeloma (MM) patients with concomitant advanced chronic kidney disease (CKD) are poorly understood, limited, and controversial. Material And Methods: We retrospectively analysed 44...
3.
Zolotov E, Patel V, Weiss Y, Biran N, Phull P, Vesole D, et al.
Eur J Haematol
. 2024 Dec;
114(3):500-507.
PMID: 39638636
Venetoclax, the first-in-class BCL-2 inhibitor, has shown efficacy in multiple myeloma (MM), particularly in patients with the t(11;14) translocation. This single-center retrospective analysis included MM patients treated with venetoclax from...
4.
Charlinski G, Szudy-Szczyrek A, Podgajna M, Mielnik M, Kopinska A, Tyczynska A, et al.
Adv Clin Exp Med
. 2024 Aug;
PMID: 39206811
Background: Non-secretory multiple myeloma (NSMM) accounts for approx. 2-3% of multiple myeloma (MM) cases. Due to the rare occurrence and ineligibility of patients with NSMM to participate in clinical trials,...
5.
Charalampous C, Doucette K, Chappell A, Vesole D
Leuk Lymphoma
. 2024 Aug;
65(12):1901-1904.
PMID: 39088749
No abstract available.
6.
Zolotov E, Kabat M, Parmar H, Anand P, Zenreich J, Aleman A, et al.
Leuk Lymphoma
. 2024 Jul;
65(13):2000-2008.
PMID: 39082756
Patients with high-risk multiple-myeloma (HRMM) and ultra-high-risk multiple-myeloma (UHRMM) show rapid disease progression and shorter survival compared to those with standard-risk multiple-myeloma (SRMM). Lenalidomide maintenance after autologous stem cell transplant...
7.
Pasquini M, Wallace P, Logan B, Kaur M, Tario J, Howard A, et al.
J Clin Oncol
. 2024 May;
42(23):2757-2768.
PMID: 38701390
Purpose: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on...
8.
Charlinski G, Steinhardt M, Rasche L, Gonzalez-Calle V, Pena C, Parmar H, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672674
Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One of the most common...
9.
Bangolo A, Oza S, Reich-Slotky R, Chappell A, Siegel D, Parmar H, et al.
Curr Stem Cell Res Ther
. 2024 Apr;
20(2):211-217.
PMID: 38584546
Background: Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the neoplastic proliferation of plasma cells, which produce monoclonal immunoglobulin that can cause vital organ damage, subsequently leading to...
10.
Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686635
Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients...